MAUDE MDR 7982260

MDR report key
7982260
Report number
2028492-2018-00012
Event key
0
Event type
3
Date of event
2018-08-15
Date received
2018-10-18
Adverse event
3
Product problem
3
Patients in event
0
Reporter occupation
1
Health professional
3
Initial report to FDA
3
Event location
3

Manufacturer Contact#

Contact
NA TIM GIBLIN
Address
1910 EAST INNOVATION PARK DR NA TUCSON AZ 85755 US
Phone
520-520-5208
Report source
M
Manufacturer link flag
Y

Devices#

Seq, Brand, Generic table
SeqBrandGenericManufacturerProduct codeModelCatalogLotPMA510(k)ImplantEvaluatedAvailability
1TTF-1 (SP141) PABTTF1VENTANA MEDICAL SYSTEMS INCNJT06640613001790-4756E03354R *

Patients#

Sequence, Received, Treatment table
SequenceReceivedTreatmentOutcome
12018-10-1801. O

Event Narratives#

N

Patient 1

PER PACKAGE INSERT: INTENDED USE: ANTI-THYROID TRANSCRIPTION FACTOR-1 (SP141) RABBIT MONOCLONAL PRIMARY ANTIBODY (ANTI-TTF-1 (SP141) IS DIRECTED AGAINST THE THYROID TRANSCRIPTION FACTOR-1 (TTF-1) PROTEIN. THIS ANTIBODY EXHIBITS A NUCLEAR STAINING PATTERN AND MAY BE USED TO AID IN THE CLASSIFICATION OF NEOPLASMS OF THE LUNG AND THYROID. THIS ANTIBODY IS INTENDED FOR QUALITATIVE STAINING IN SECTIONS OF FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE. THIS PRODUCT SHOULD BE INTERPRETED BY A QUALIFIED PATHOLOGIST IN CONJUNCTION WITH HISTOLOGICAL EXAMINATION, RELEVANT CLINICAL INFORMATION, AND PROPER CONTROLS. THIS ANTIBODY IS INTENDED FOR IN VITRO DIAGNOSTIC (IVD) USE. SUMMARY AND EVALUATION: EXPRESSION OF TTF-1 HAS NOW BEEN IDENTIFIED IN TISSUES AND TUMORS PREVIOUSLY THOUGHT TO BE NEGATIVE WITH THE USE OF NEWER CLONES AND DETECTION SYSTEMS. LITERATURE PUBLISHED OVER THE PAST FEW YEARS HAS DEMONSTRATED EXPRESSION OF TTF-1 BEING DETECTED IN NEOPLASTIC TISSUE BEYOND LUNG AND THYROID. RATIONALE: ASSAY IS A ADJUNCT ASSAY USED TO AID IN THE CLASSIFICATION OF NEOPLASMS OF THE LUNG AND THYROID. PER MEDICAL OPINION: CASE DETAILS DO NOT PROVIDE EVALUATION OF THE H&E, A PANEL OF STAINS IS PERFORMED TO RULE IN AND RULE OUT VARIOUS DIAGNOSTIC POTENTIALS. ASSAY WAS POSITIVE DURING INITIAL RUN AND RE-RUN SUPPORTING NO MALFUNCTION OF ASSAY. ASSAY RAN AS INTENDED PER PACKAGE INSERT.

D

Patient 1

PATIENT WENT TO THE HOSPITAL. A LUNG TUMOR WAS EXPECTED. A LUNG BIOPSY WAS TAKEN. THIS BIOPSY WAS POSITIVE FOR TTF-1 SP141 (LOT# (B)(4)) WHICH MEANS AN ADENOCARCINOMA OF THE LUNG. THIS SAMPLE WAS VERY POSITIVE, LUNG CONTROL TISSUE ON THE SAME SLIDE STAINED APPROPRIATE AS WELL. THIS PATIENT WAS SENT TO ANOTHER HOSPITAL SINCE TUMOR OUTGROWTH IN THE "TORAX" WAS DIAGNOSED. A SURGERY WAS PERFORMED BASED ON THE TTF-1 RESULTS. JUST AS CONTROL, A TTF-1 STAINING HAS BEEN PERFORMED AFTER THE SURGERY IN THIS HOSPITAL WHERE THE SURGERY HAS BEEN PERFORMED (DAKO OMNIS STAINING PLATFORM, TTF-1 DAKO ANTIBODY): STAINING NEGATIVE FOR TTF-1. THIS MEANS THAT IT COULD NOT BE AN ADENOCARCINOMA OF THE LUNG AND THAT THE WRONG TREATMENT MIGHT HAVE BEEN PERFORMED. ADDITIONAL STAININGS HAVE BEEN PERFORMED. THIS TUMOR STAINS POSITIVE FOR B-CELL LYMPHOMA ON THE DAKO OMNIS.